Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neurodegeneration Clear all
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational

Mitochondrial Dysfunction and Disease Progression

NCT02549703
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 22, 2026, 2:13 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

NCT06597058
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MAR
Drug
Lead sponsor
Noah Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Not listed No phase listed Observational

NBIAready: Online Collection of Natural History Patient-reported Outcome Measures

NCT02587858
View directory record Official record
Conditions
Neurodegeneration With Brain Iron Accumulation (NBIA)
Interventions
Not listed
Lead sponsor
Susan J. Hayflick
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study

NCT02488720
View directory record Official record
Conditions
Cognition Disorders
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 85 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 2:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)

NCT04124029
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
Interventions
No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Device · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

NCT03076671
View directory record Official record
Conditions
Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions
Palliative Care
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 105 Years
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 22, 2026, 2:13 AM EDT
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
View directory record Official record
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury

NCT04820881
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Not listed
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional

Genes, Exercise, Memory and Neurodegeneration

NCT01021644
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
aerobic exercise-training, stretch exercise
Behavioral
Lead sponsor
Howard University
Other
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 22, 2026, 2:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Microbiome, Anxiety and Cognitive Orientation Study

NCT05388630
View directory record Official record
Conditions
Anxiety, Microbiome, Mood Disorders, Neurodegeneration, Depression
Interventions
Not listed
Lead sponsor
Endominance
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 22, 2026, 2:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biofluid Research on Age-Related or Inherited Neurodegeneration

NCT07798700
View directory record Official record
Conditions
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

NCT07348250
View directory record Official record
Conditions
Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
Interventions
[18F]MK-0947
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

NCT06169150
View directory record Official record
Conditions
Nervous System Disease, Immune System Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 120 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2043
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach

NCT02614365
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aerobic exercise, Stretch exercise
Behavioral
Lead sponsor
Howard University
Other
Eligibility
55 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

NCT01741532
View directory record Official record
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
Deferiprone oral solution, Placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
4 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia

NCT01776164
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis

NCT02651545
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia

NCT00078481
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Idebenone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Novel PET Radioligand to Image OGA

NCT03632226
View directory record Official record
Conditions
Pharmacokinetics, Adult
Interventions
18F-OGA-1
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

NCT04182763
View directory record Official record
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
CoA-Z, Placebo
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Months to 89 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 22, 2026, 2:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation

NCT07588581
View directory record Official record
Conditions
Childhood-Onset Neurodegeneration With Brain Atrophy (CONDBA)
Interventions
nL-UBTF-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Early Parkinson's Disease Monotherapy With CVN424

NCT06006247
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance Beta, Inc.
Industry
Eligibility
30 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 2:13 AM EDT